Menomune

Menomune

(men′ŏ-mūn″)
A freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis.
References in periodicals archive ?
Browse Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo) and Forecast 2017-2021 at https://www.
Although neither meningococcal conjugate vaccine product is licensed for use in individuals 56 years or older, ACIP recommends using one of the products for HIVinfected individuals in this age group because the only meningococcal vaccine licensed for use in adults 56 or older, meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur), has not been studied in patients with HIV infection.
Meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur) is the only licensed meningococcal vaccine for adults aged [greater than or equal to] 56 years; however, no data are available on use of MPSV4 in HIV-infected adults.
In a separate advisory, the FDA warned against falsified meningitis vaccines Menomune ACY-W135 (10 doses/vial) with batch numbers UH301AA (with expiry dates 29 April 2017 and 28 February 2016) and UH299AA; and diluent for Menomune with batch numbers UH262AA and D0953-1.
Menomune (Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined) is the brand name for Sanofi's tetravalent polysaccharide vaccine sold in the US and Australia to protect against four N.
In 1982, a quadrivalent polysaccharide vaccine (MPSV-4; Menomune, Sanofi Pasteur, Bridgewater, NJ, USA) was introduced; this vaccine targets serogroups A, C, W-135, and Y.
Menomune (sanofi pasteur)--meningococcal polysaccharide
A third nonrandomized group of 150 3- to 5-year-old children received a single dose of Menomune vaccine, which contains N.
ACIP also voted separately to include coverage for both Menactra and Menomune in the Vaccines for Children (VFC) Program, an entitlement program under the Social Security Act that went into effect in October 1994 to provide vaccines free to physicians caring for children whose families cannot afford them.
meningitidis serogroup C, compared with 79% of the control group of older children vaccinated with a single dose of Menomune.
Expected to have several advantages over Menomune, the currently available polysaccharide meningococcal vaccine that also protects against these serogroups.
Menactra offers several potential advantages over Menomune, including immune memory, a better booster effect, reduction of carriage, and herd immunity, said Dr.